Genelux (US:GNLX) Globenewswire·2026-01-05 13:00Core Insights - Genelux Corporation announced interim results from ongoing trials evaluating Olvi-Vec in patients with progressive lung cancers, showing promising anti-tumor activity and tolerability [1][3][5] Group 1: Trial Results - In the Phase 1b/2 SCLC trial, 33% of patients (3 out of 9) achieved partial responses (PRs), with significant tumor shrinkage observed in the highest dose cohort [1][5] - The overall response rate (ORR) in the highest dose cohort (Cohort 4) was 67% (2 out of 3 patients), indicating a potential dose-response trend [5] - The disease control rate (DCR) was 67% (6 out of 9 patients), with tumor shrinkage ranging from 24% to 85% among DCR patients [5][12] Group 2: Future Expectations - Additional data from the SCLC and NSCLC trials are expected throughout 2026, with topline data from the Phase 3 ovarian cancer trial anticipated in the second half of 2026 [1][13] - The company aims to optimize the efficacy, safety, and tolerability of Olvi-Vec through ongoing dose escalation cohorts [8] Group 3: Mechanism and Development - Olvi-Vec is designed to resensitize tumors to platinum-based chemotherapy and is being evaluated across multiple solid tumor types [2][9] - The company has administered Olvi-Vec to over 150 patients across seven completed clinical trials, demonstrating general tolerability and clinically meaningful benefits [9]